Zai Lab Limited develops and commercializes products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; VYVGART, a human IgG1 antibody fragment for myesthenia gravis; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; Qinlock to treat gastrointestinal stromal tumors; Xacduro, a combination of a beta-lactam antibiotic (sulbactam) and a beta-lactamase inhibitor (durlobactam) for the treatment of serious infections caused by acinetobacter; and Augtyro, a tyrosine kinase inhibitor ROS1 oncogenic fusions. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and its immunology, neuroscience, and infectious disease pipeline includes efgartigimod and xanomeline and trospium chloride. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is based in Shanghai, China.

Zai Lab Limited

In a report released on November 7, from UBS maintained a Buy rating on Zai Lab Ltd, with a price target of HK$33.50. The company’s shares closed l...

Zai Lab Ltd (1ZLB) Gets a Buy from UBS

Zai Lab Ltd (($ZLAB)) has held its Q3 earnings call. Read on for the main highlights of the call. Zai Lab Ltd’s recent earnings call presented a mi...

Zai Lab Ltd’s Earnings Call: Mixed Outlook Amid Growth and Challenges

In a report released today, David Li from Bank of America Securities reiterated a Hold rating on Zai Lab, with a price target of $25.70. Li covers ...

Current Quarter	$-0.38	Next Quarter	$NA
Current Year	$-1.5	Next Year	$-0.74
QoQ Growth	NaN%	YoY Growth	+50.7%
3Y EPS CAGR	+0.0%	Target Price	$51.46
Consensus	Buy	Upside	+157.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ZLAB	$20.02	-0.94%	631.53K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ZLAB	$20.02	-0.9%	631.53K
3
4
5
6

ZLAB

ZLAB

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Zai Lab Limited Data in Excel

Get Zai Lab Limited Data in Excel